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Increased urinary albumin excretion is astrong predictor of cardiovascular diseaseand mortality in patients with type 2 dia-
betes as well as in nondiabetic subjects. The
pathophysiological explanation for this asso-
ciation is not entirely clear, but the risk
marker albuminuria has been associated
with the presence of several cardiovascular
risk factors, including hypertension, dys-
lipidemia, poor glycemic control, a pro-
thrombotic state, and generalized endothe-
lial dysfunction (1).
Cardiovascular autonomic neuropa-
thy is also strongly related to cardiovascu-
lar mortality in type 2 diabetes (2,3). Sev-
eral studies have suggested that impaired
cardiovascular autonomic function and
increased urinary albumin excretion are
related in patients with diabetes (4–8). Most
of these studies have been done in type 1
diabetes. Similar studies in type 2 diabetes
were relatively small or did not include sub-
jects with normal glucose tolerance (NGT)
and impaired glucose tolerance (IGT) for
comparison with subjects with type 2 dia-
betes (9–14). In the present study, we
investigated the relationship between car-
diovascular autonomic function and albu-
minuria by using data from a large popula-
tion-based study including subjects with
NGT and IGT and type 2 diabetes. We
were specifically interested in determining
whether autonomic cardiovascular func-
tion is related to albuminuria indepen-
dently of other factors that are known to be
associated with albuminuria, including glu-
cose intolerance and hypertension.
RESEARCH DESIGN AND 
METHODS
Subjects
The Hoorn Study is a cross-sectional inves-
tigation of glucose tolerance and other car-
diovascular risk factors in a Caucasian
population that was conducted from 1989
to 1992. A random sample of all men and
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Cardiovascular Autonomic Function Is
Associated With (Micro-)Albuminuria in
Elderly Caucasian Subjects With Impaired
Glucose Tolerance or Type 2 Diabetes
The Hoorn Study
O R I G I N A L  A R T I C L E
OBJECTIVE — To determine whether impaired cardiovascular autonomic function corre-
lates with albuminuria in an age-, sex-, and glucose tolerance–stratified sample of an elderly
(50–75 years of age) Caucasian population and to determine whether this association is inde-
pendent of other determinants of albuminuria.
RESEARCH DESIGN AND METHODS — We studied 536 subjects, 256 with normal
glucose tolerance, 143 with impaired glucose tolerance (IGT), and 137 with type 2 diabetes.
Microalbuminuria was defined as an albumin-to-creatinine ratio of 3.0 and 30 mg/mmol
in an early morning urine sample. We used the deep-breathing test and the lying-to-standing
test to obtain 4 measurements of cardiovascular autonomic function: 1) the heart rate (HR)
variability during deep breathing, 2) the maximum HR within 15 s after standing up minus the
mean HR before standing, 3) the maximum R-R interval between 15 and 30 s after standing
up divided by the minimum R-R interval within 15 s after standing up, and 4) the systolic blood
pressure in response to standing up. These 4 measurements were summarized in a single car-
diovascular autonomic function score (CAFS).
RESULTS — A total of 38 subjects with microalbuminuria and 3 subjects with macroalbu-
minuria (30 mg/mmol) were grouped as having albuminuria. In bivariate analyses, albumin-
uria was associated with age, waist-to-hip ratio, systolic and diastolic blood pressure, calculated
glomerular filtration rate, and glucose tolerance status. The mean CAFS was higher in subjects
with versus without albuminuria (7.5 vs. 5.9, P  0.001). Multiple logistical regression analy-
ses revealed that the CAFS was independently associated with albuminuria in subjects with IGT
or type 2 diabetes with an odds ratio (95% CI) of 1.19 (1.02–1.39) per point increase in the CAFS.
CONCLUSIONS — Impaired cardiovascular autonomic function is independently associ-
ated with (and thus a possible contributor to) the presence of albuminuria in subjects with IGT
or type 2 diabetes.
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women 50–75 years of age was drawn from
the municipal population registry of the
town of Hoorn, the Netherlands. A total of
2,484 subjects participated (response rate
71%). An extensive cardiovascular investi-
gation was performed in an age-, sex-, and
glucose tolerance–stratified random sub-
sample (n = 631, response rate 89%) as
described in detail elsewhere (15). The
Hoorn Study was approved by the Ethical
Review Committee of the University Hos-
pital Vrije Universiteit. Informed consent
was obtained from all participants.
Measurements
Height and weight were measured while
subjects were barefoot and wearing light
clothes only. Double readings of systolic
and diastolic (Korotkoff V) blood pressure
levels were obtained on 2 separate occasions
in a sitting position. Actual hypertension
was defined as mean systolic blood pressure
160 mmHg and/or mean diastolic blood
pressure 95 mmHg with or without anti-
hypertensive medication. IGT and type 2
diabetes were diagnosed according to the
1985 World Health Organization criteria
applied to the mean of 2 standard oral glu-
cose tolerance tests (16). Fasting and 2-h
postload venous plasma glucose levels were
determined with a glucose dehydrogenase
method. Subjects with previously diag-
nosed type 2 diabetes treated with oral
medication or insulin did not undergo a
glucose tolerance test. We measured fasting
serum levels of total cholesterol, HDL cho-
lesterol, and triglycerides (enzymatic tech-
niques); creatinine (modified Jaffé method);
and total homocysteine and HbA1c (high-
performance liquid chromatography).
Glomerular filtration rate was estimated
from serum creatinine using the formula
described by Levey et al. (17). Albuminuria
was measured in an early morning first
voided urine sample. The presence of
leukocytes was tested by light microscopy
and scored as positive if 5 leukocytes/
high-power field were found. Albumin con-
centration was measured by rate neph-
elometry (Array Protein System; Beckman,
Galway, Ireland) with a detection threshold
of 6.2 mg/l and intra- and interassay coeffi-
cients of variation of 5 and 8%, respectively.
Urinary creatinine was measured with a
modified Jaffé method. A urinary albumin-
to-creatinine ratio of 3.0 mg/mmol was
taken as the lower cutoff value for microal-
buminuria, and a ratio of 30 mg/mmol
was defined as macroalbuminuria. Urine
samples were available for a total of 607
subjects. Subjects using an ACE inhibitor (n
= 32) were excluded to avoid misclassifica-
tion of the dependent variable, which left
575 subjects for further analysis. Protein
intake was calculated using a self-adminis-
tered validated semiquantitative food fre-
quency questionnaire (18).
A detailed cardiovascular history was
obtained from all subjects and, if positive,
was accepted only when confirmed in writ-
ing by the subject’s general practitioner.
Cardiovascular disease was defined as coro-
nary artery, cerebrovascular, or peripheral
artery disease. All subjects with cardiovas-
cular disease and those using drugs affect-
ing the cardiovascular system (including
antihypertensive and antiarrhythmic drugs,
-blockers, diuretics, and vasodilators)
were classified as positive for cardiovascu-
lar disease and/or drugs (CVD&D).
Cardiovascular autonomic function
tests
Both the deep-breathing test and the lying-
to-standing test were performed by the
same investigator. Subjects refrained from
smoking and drinking coffee for at least 2 h
before the tests. A light meal at least 1 h
before the measurements was allowed. The
tests were done in quiet surroundings with
a room temperature between 19 and 22°C.
After 10 min of rest in a supine position,
the deep-breathing test was performed by
breathing deeply for 1 min at a frequency of
6 breaths/min (5 s in, 5 s out). After 5 min
of rest, the lying-to-standing test was per-
formed. The subjects stood up as quickly as
possible and remained standing for 2 min.
During both tests, heart rate (HR) and
blood pressure were registered using a
computer-based data acquisition system.
An electrocardiographic registration was
obtained from bipolar chest leads. Beat-to-
beat systolic and diastolic blood pressure
levels were measured noninvasively on the
right middle finger with the Finapress
(Type BP2300; Ohmeda, Englewood, CO).
The following measures of cardiovas-
cular autonomic function were used.
• EIHRdiff (beats/min): the difference
between intrabreath maximum and min-
imum HR averaged over 6 breaths,
• L→SHRmax (beats/min): the maximum
HR within 15 s after standing up minus
the mean HR during 1 min before
standing,
• L→Smax/min ratio (dimensionless): the max-
imum R-R interval between 15 and 30 s
after standing up divided by the mini-
mum R-R interval within 15 s after
standing up, and
• L→SBPsys (mmHg): the systolic blood
pressure after standing up (mean between
1.5 and 2.0 min after standing) minus
the supine systolic blood pressure (mean
of 30 s).
The EIHRdiff and the L→SHRmax predomi-
nantly reflect parasympathetic function, the
L→Smax/min ratio is the result of a vagal reflex
to sympathetically mediated vasoconstric-
tion, and the L→SBPsys is considered to
reflect mainly peripheral sympathetic func-
tion. However, the specificity of these tests
for the 2 different types of autonomic func-
tion is limited (19,20). Results were dis-
carded if multiple nonsinus beats occurred
during testing, if standing up took 10 s, or
if the recordings were technically unsuc-
cessful for 1 of the 4 measurements (n =
30). Subjects with a history of neurological
diseases or drug use known to influence
autonomic nerve function (e.g., anti-Parkin-
son’s drugs; phenytoin; antihistamines; and
parasympathicolytic, sympathicomimetic,
and parasympathicomimetic drugs) were
also excluded from the analysis (n = 9),
which left 536 subjects for final inclusion.
Statistical methods
Routine bivariate tests were used to test for
group differences between subjects with
and without albuminuria. Correlations
between the 4 autonomic function mea-
sures were calculated using Pearson’s cor-
relation coefficients, if required after
log-transformation. Based on the 4 mea-
sures of cardiovascular autonomic func-
tion, a summary cardiovascular autonomic
(dys)function score (CAFS) was con-
structed as follows. First, the results of each
measurement were divided into quartiles. A
subject was assigned 0 points if the result
was in the most normal quartile (lowest
values for the L→SBPsys test, highest val-
ues for the other 3 measures), 1 point if the
result was in the second quartile, 2 points
if the result was in the third quartile, and 3
points if the result was in the most abnor-
mal quartile (highest values for the L→S-
BPsys, lowest values for the other
measures). If all 4 measures were com-
pleted successfully, then the scores of each
were added together. If 1 result was missing
(44 of 536 subjects), then it was replaced
by the median score (1.5 points). The result
is a CAFS ranging from 0 (good) to 12
(poor). Multiple logistical regression analy-
sis was used to identify independent corre-
lates of albuminuria. The presence of inter-
action effects was studied by entering prod-
uct terms into the model.
RESULTS — Of the 536 subjects
included, 256 had NGT, 143 had IGT, and
137 had type 2 diabetes. Subjects with
microalbuminuria (n = 38) and with
macroalbuminuria (n = 3) were grouped as
having albuminuria. In the 3 categories of
glucose tolerance, 4% of NGT, 7.5% of
IGT, and 18% of type 2 diabetic subjects
had albuminuria (P  0.001 by 2). Demo-
graphic and clinical data of subjects with
and without albuminuria are shown in
Table 1. Age, waist-to-hip ratio, BMI, blood
pressure, glomerular filtration rate, and glu-
cose tolerance were significantly related to
the presence of albuminuria in bivariate
tests. All 4 measures of cardiovascular auto-
nomic function showed less favorable
results in subjects with albuminuria.
Table 2 displays the difference in CAFS
between subjects with and without albu-
minuria, with separate results given for
substrata of glucose tolerance and actual
hypertension. In the entire group, the
CAFS was significantly related to albumin-
uria. This relationship did not vary greatly
with glucose tolerance status or the pres-
ence of hypertension. No evidence existed
of a threshold effect in the relationship
between the CAFS and albuminuria (data
not shown). As shown in Table 2, the CAFS
itself was closely related to glucose toler-
ance; the means ± SD CAFS was 5.4 ± 2.7
in NGT, 6.1 ± 2.9 in IGT, and 7.1 ± 2.8 in
type 2 diabetic (P  0.001 by analysis of
variance) subjects.
In multivariate analysis, none of the
individual associations between the 4 sep-
arate measures of cardiovascular autonomic
function and albuminuria retained statisti-
cal significance after adjustment for poten-
tial confounders (data not shown). The
CAFS, however, was independently related
to the presence of albuminuria in the com-
plete study group (Table 3). Multiple logis-
tical regression analysis was also performed
in strata of glucose tolerance. In these
analyses, the IGT and the type 2 diabetic
subjects behaved similarly regarding the
association between the CAFS and albu-
minuria; the odds ratio (95% CI) (calcu-
lated as in model 2 of Table 3) for having
albuminuria was 1.26 (0.97–1.64) for IGT
and 1.22 (0.98–1.52) for type 2 diabetes.
Because of this similarity—and its contrast
with the results obtained for NGT—sub-
jects with IGT and type 2 diabetes were
analyzed as a single group. The analyses
suggested that the association between
CAFS and albuminuria was stronger in
subjects with IGT or type 2 diabetes than in
NGT subjects (Table 3). Additional adjust-
ment for HbA1c or fasting glucose levels in
the IGT and type 2 diabetes group did not
materially affect these results (data not
shown). Adjustment solely for age rather
than for all of the stratification variables
(model 1) was also performed. The odds
ratios then were 1.18 (1.04–1.34) for all sub-
jects, 1.02 (0.80–1.31) for the NGT group,
and 1.19 (1.03–1.38) for the IGT and type 2
diabetes group, which indicates that the
effect of adjustment for the stratification vari-
ables, especially in the NGT group, is
explained mainly by the effect of age.
Note that we performed 2 measure-
ments reflecting mainly parasympathetic
function, 1 that reflects mainly sympathetic
function, and 1 that combines parasympa-
thetic and sympathetic function. Combining
the 4 autonomic function measures in 1
score carries the risk of unbalanced weight-
ing of parasympathetic and sympathetic
autonomic function. Therefore, we also con-
structed an alternative autonomic function
score by combining the EIHRdiff (mainly
parasympathetic) and the L→SBPsys
(mainly sympathetic) in a similar manner as
was done for the CAFS. The EIHRdiff was
chosen as the parasympathetic test because
it showed the lowest correlation with the
L→SBPsys, indicating minimal colinearity.
This alternative score resulted in odds ratios
that were virtually identical to those reported
for the CAFS in Table 3 (data not shown).
No evidence of an interactive effect
between any measure of blood pressure
and the CAFS regarding the occurrence of
albuminuria was found. Likewise, we
found no evidence of interaction between
CAFS and age, waist-to-hip ratio, or protein
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Table 1—Demographic and clinical data of normoalbuminuric and albuminuric subjects
Normoalbuminuric Albuminuric
subjects subjects P
n 495 41 —
Age (years) 63.7 ± 7.1 66.7 ± 6.0 0.009
Sex (M) 47 54 0.40
Waist-to-hip ratio
Men 0.96 ± 0.07 0.97 ± 0.06 0.55
Women 0.87 ± 0.08 0.93 ± 0.05 0.001
BMI (kg/m2) 26.9 ± 3.7 28.6 ± 4.8 0.008
Systolic blood pressure (mmHg) 136.7 ± 18.2 152.4 ± 20.2 0.001
Diastolic blood pressure (mmHg) 81.9 ± 9.5 87.4 ± 12.0 0.001
Mean arterial blood pressure (mmHg) 100.2 ± 11.3 109.0 ± 13.1 0.001
Actual hypertension 14 44 0.001
NGT/IGT/type 2 diabetes 50/27/23 24/24/52 0.001
HbA1c (%) 5.5 (2.7–15.2) 6.0 (4.5–12.1) 0.002
Total cholesterol (mmol/l) 6.7 ± 1.2 6.6 ± 1.2 0.68
HDL cholesterol (mmol/l) 1.25 (0.56–3.43) 1.10 (0.57–2.29) 0.08
Triglycerides (mmol/l) 1.5 (0.4–14.0) 1.8 (0.7–13.9) 0.12
Currently smoking (yes) 28 27 0.84
Protein intake (g 	 kg
1 	 day
1) 0.95 (0.29–2.38) 0.90 (0.31–1.80) 0.56
Homocysteine (µmol/l) 11.3 (4.9–49.6) 12.4 (6.1–77.5) 0.20
Glomerular filtration rate (ml/min) 71.5 ± 19.7 61.8 ± 18.6 0.003
Autonomic function measures
EIHRdiff (beats/min) 10.7 (1.9–42.7) 8.7 (2.5–29.4) 0.27
L→SHRmax (beats/min) 20.6 (6.5–46.4) 17.3 (6.3–34.3) 0.001
L→Smax/min ratio 1.22 (1.0–2.1) 1.18 (1.0–1.6) 0.02
L→SBPsys (mmHg) 
5.8 ± 15.5 
9.4 ± 13.5 0.12
Data are means ± SD with P values calculated by an unpaired t test, medians (ranges) with P values calculated
by the Mann-Whitney U test, or %. P values for nominal variables are calculated with the 2 test (for glucose
tolerance categories, 2 test for trend). Albuminuria is the albumin-to-creatinine ratio 3.0 mg/mmol in an early
morning spot urine sample. Mean arterial blood pressure is diastolic blood pressure  (0.33  pulse pressure).
Actual hypertension is systolic blood pressure 160 mmHg and/or diastolic blood pressure 95 mmHg.
Glomerular filtration rate was calculated with the formula of Levey et al. (17). For explanation of autonomic
function tests, see RESEARCH DESIGN AND METHODS.
intake. Reanalysis of the data with albumin-
to-creatinine ratios of 2.0 and 2.5 as lower
cutoffs for albuminuria had trivial effects on
the outcomes, as did exclusion of subjects
with leukocyturia (n = 121) and exclusion
of the 3 subjects with macroalbuminuria. If
hypertension defined as systolic and dias-
tolic blood pressure levels of 160 and/or
95 mmHg, respectively, and/or use of
antihypertensive medication was entered
instead of actual hypertension, then the
results as presented in Table 3 were essen-
tially identical (data not shown). Also,
exclusion of subjects with actual hyperten-
sion from the analyses had trivial effects on
the results. Finally, replacing waist-to-hip
ratio with BMI did not change the out-
come of any of the multivariate analyses.
A total of 192 subjects met the criteria
for CVD&D. After adjustment for CVD&D
in the IGT and type 2 diabetes subgroup, the
odds ratio for the CAFS decreased slightly to
1.16 (1.00–1.34) and 1.14 (0.98–1.34) in
models 1 and 2, respectively (from 1.20 and
1.19, respectively [Table 3]).
CONCLUSIONS — This study demon-
strates that cardiovascular autonomic func-
tion is related to the presence of albuminuria
in an age-, sex-, and glucose tolerance–strat-
ified random sample of an elderly Caucasian
population. This association was indepen-
dent of other determinants of albuminuria in
the Hoorn Study population (e.g., glucose
tolerance, blood pressure, waist-to-hip ratio,
protein intake, and homocysteine [21,22])
except for the fact that it was observed more
clearly in subjects with IGT or diabetes than
in NGT subjects. In subjects with NGT, the
apparent correlation between autonomic
function and albuminuria was almost fully
explained by the effect of age, which was not
an evident confounder of this correlation in
IGT and type 2 diabetes. The subgroup
analyses should, however, be interpreted
with some caution because they apply to a
much smaller number of subjects, and the
CIs of the subgroups show overlap.
Although the definitions of autonomic
dysfunction are not uniform, the overall
reported prevalence of autonomic dysfunc-
tion is 7% in newly diagnosed type 2 dia-
betes (23). Autonomic dysfunction appears
to be associated with age (11), sex (24),
weight (9,13), blood pressure (9,11), fasting
insulin level (9,24), glycemic control (13),
and duration of type 2 diabetes (13,24). As
for type 2 diabetes–related microvascular
complications, several reports have sug-
gested an association between autonomic
dysfunction and retinopathy (11,13,25).
Some studies have examined autonomic
cardiovascular function in detail in relation
to albuminuria in type 2 diabetes. An early
study found higher urinary albumin excre-
tion rates in patients with impaired HR vari-
ability, which is a feature of cardiovascular
autonomic failure (9). Another report indi-
cated that autonomic cardiovascular dys-
function measured with only a single test
(deep breathing) was related to macroalbu-
minuria in a large (n = 949) sample of rela-
tively young and strictly hypertensive
patients (13). In this study, normo- and
microalbuminuric subjects were taken as a
single control group. An abnormal
day–night blood pressure pattern was
related to abnormal autonomic function
measures and proteinuria in a study involv-
ing 76 subjects (10). Two small studies have
shown conflicting results (11,12). Finally, a
recent study found that albuminuria was
related to Valsalva and breathing ratios only
in patients with a duration of type 2 dia-
betes of 1 year (14). Compared with these
previous studies, our study has the advan-
tage of being large (which allows the use of
multivariate tests), being truly population
based, and including patients with NGT
and IGT and with normal and increased
blood pressure levels. Also, we were able to
include 4 different measures of autonomic
function. Previous studies used less exten-
sive autonomic function tests except for 1
(11) that unfortunately included only 9 type
2 diabetic patients with albuminuria.
Two explanations exist for a possible
causal relationship between cardiovascular
autonomic function and urinary albumin
excretion. First, a reduced nightly drop in
blood pressure, which is a feature of auto-
nomic dysfunction not only in type 1 dia-
betes but also in type 2 diabetes (26), may
result in albuminuria. Second, a distur-
bance in glomerular arteriolar autoregula-
tion may result in an inability of the
glomerular apparatus to counteract hyper-
glycemia-associated glomerular hyperten-
sion and hyperfiltration (27). Glomerular
hyperfiltration has been reported to occur
in type 2 diabetes but has also been found
in subjects with IGT (28). Our findings
may indicate that IGT- and type 2 dia-
betes–associated effects on glomerular
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Table 2—Mean CAFS in normoalbuminuric and albuminuric subjects
Normoalbuminuric Albuminuric
subjects subjects P
All 5.9 (495) 7.5 (41) 0.001
NGT 5.4 (246) 6.4 (10) 0.15
IGT 6.0 (133) 7.5 (10) 0.10
Type 2 diabetes 6.9 (116) 8.0 (21) 0.08
No actual hypertension 5.8 (428) 7.4 (23) 0.006
Actual hypertension 6.4 (67) 7.6 (18) 0.10
Data in parentheses indicate n. Actual hypertension was defined as systolic blood pressure 160 mmHg and/or
diastolic blood pressure 95 mmHg with or without use of antihypertensive medication. All P values were cal-
culated with the unpaired t test.
Table 3—Multiple logistical regression analyses with albuminuria as the dependent variable and
the CAFS as the independent variable
Crude model Model 1 Model 2
All subjects 1.22 (1.08–1.37) 1.15 (1.01–1.30) 1.14 (1.00–1.31)
NGT 1.14 (0.91–1.44) 1.03 (0.81–1.32) 1.05 (0.81–1.38)
IGT and type 2 diabetes 1.20 (1.04–1.39) 1.20 (1.04–1.39) 1.19 (1.02–1.39)
Data are odds ratios (95% CIs). The odds ratio is expressed for each point increase in the autonomic cardio-
vascular function score. Separate results are given for the complete study group and for the substrata of NGT
and IGT plus type 2 diabetes. For all subjects, model 1 included adjustment for age, sex, and glucose tolerance
category. Model 2 was the same as model 1 plus adjustment for actual hypertension, waist-to-hip ratio, triglyc-
erides, and HDL cholesterol. In substrata of glucose tolerance, models 1 and 2 were identical but without glu-
cose tolerance as a covariate. Additional adjustment for glomerular filtration rate, total protein intake,
homocysteine, and current or ever smoking provided results virtually identical to model 2 in both the entire
group and each of the substratum analyses (data not shown).
hemodynamics may be required for auto-
nomic cardiovascular dysfunction to reveal
its effect on albuminuria.
Another possibility is that the associa-
tion we found is not causal but simply
reflects an association between 2 diabetic
complications caused by largely the same set
of risk factors. However, if this is the case,
then the introduction of these risk factors as
additional independent variables on top of
the crude model with only the CAFS would
have introduced significant colinearity
among the independent variables. This
would normally be reflected by a marked
decrease in the odds ratio and/or in the par-
tial R2 for the CAFS, which was not seen (the
partial R2 for the CAFS in the IGT and type
2 diabetes stratum was 0.15 in the crude
model, 0.14 in model 1, and 0.12 in model
2 [Table 3]). Even if the association at issue
does not reflect causality between albumin-
uria and cardiovascular autonomic function,
our results may still be important in the
context of understanding why albuminuria
predicts mortality in type 2 diabetes. Many
believe that this prognostic significance of
albuminuria is explained by its association
with several atherosclerotic risk factors,
including hypertension, dyslipidemia,
smoking, and poor glycemic control. How-
ever, albuminuria still predicts cardiovascu-
lar events after adjustment for these risk
factors (29). Two explanations may exist for
this. First, albuminuria may reflect early gen-
eralized vascular/endothelial damage (1,30).
Alternatively, cardiovascular risk factors
other than those commonly studied may
hide beneath the independent prognostic
significance of albuminuria, and cardiovas-
cular autonomic neuropathy may be such a
risk factor (24,31). In fact, the only study we
know of that has included both albuminuria
and cardiovascular neuropathy as predic-
tors of cardiovascular disease in a multivari-
ate analysis found that albuminuria was no
longer a prognostic factor after adjusting for
the presence of autonomic neuropathy (3).
We did not regard the autonomic test
results as dichotomous variables for “normal”
and “abnormal” results. We chose this
approach because abnormal values for auto-
nomic function tests have been defined on
the basis of statistical abnormality in a
healthy control population rather than on the
basis of pathophysiological alterations. No
evidence exists to indicate that these statisti-
cally abnormal results have a pathophysio-
logical meaning in the context of a possible
association with albuminuria. Also, we
avoided the use of age-corrected autonomic
function measures. Albuminuria increases
with age, and whether this effect is (par-
tially) mediated by deterioration in auto-
nomic function is not known. However,
should this be the case, then removing the
age effect from the autonomic function vari-
able by using age-corrected values would
inadvertently exclude autonomic function as
a determinant of albuminuria. Adjusting for
age in the multivariate model by including it
as a separate independent variable is, in our
view, the best option. A final possible con-
cern is whether combining several auto-
nomic function measures in a single score is
legitimate. We constructed the CAFS with
the purpose of enhancing power because a
battery of autonomic function measures will
by definition show a higher reproducibility
than any single measurement. Also, the 4
measures are thought to convey distinct
information about cardiovascular autonomic
function, although the specificity for the spe-
cific subtype of autonomic function (sympa-
thetic vs. parasympathetic) should not be
overestimated (19,20). Still, the contention of
supplemental information from the 4 tests is
supported by generally poor correlations that
we found between the 4 tests. Except for a
correlation of 0.60 between the L→SHRmax
and the L→Smax/min ratio, all correlations were
0.40. Even the EIHRdiff and the L→S-
HRmax, which are both considered to reflect
mainly parasympathetic function, correlated
poorly (correlation coefficient 0.37) and were
quite differently associated with albuminuria
(Table 1). Even so, giving equal weight to
measures that overlap even partially could
possibly result in a CAFS that does not give
a balanced impression of overall autonomic
function. In our view, the virtually identical
results that were obtained using an alterna-
tive score that combined a mainly parasym-
pathetic with an uncorrelated mainly sym-
pathetic measurement make the possibility
that the CAFS was heavily unbalanced
unlikely.
In conclusion, our study shows that
autonomic cardiovascular function is asso-
ciated with the occurrence of albuminuria,
especially in subjects with IGT or type 2
diabetes, and that this association is inde-
pendent of age, blood pressure, and other
previously identified determinants of albu-
minuria in the same study population.
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